跳至主要内容
临床试验/NCT07836933
NCT07836933尚未招募不适用

Cancer Oriented Understanding and Navigation Via Supportive and Educational Language Models (COUNSEL)

University of California, San Francisco1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2026年10月31日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
尚未招募
入组人数
50
试验地点
1
主要终点
Mean differences on EORTC QLQ-INFO25 - Patient-Perceived Cancer-Related Information

研究概览

简要总结

A randomized, open-label behavioral study designed to evaluate the feasibility, acceptability, and early impact of a large language model (LLM)-based artificial intelligence (AI) tool to support patient understanding following an initial oncology consultation.

详细描述

PRIMARY OBJECTIVE:

I. To evaluate the impact of a LLM-based intervention on patients' perceived quality, breadth, and depth of cancer-related information following a radiation or surgical oncology consult.

SECONDARY OBJECTIVES:

I. To assess patient- and provider-perceived levels of shared decision making. II. To evaluate changes in patient-reported distress. III. To compare concordance between patient and provider perceptions of shared decision making.

EXPLORATORY OBJECTIVES:

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Age ≥18 years.
  • •Histologically or cytologically confirmed diagnosis of localized prostate cancer
  • •Newly diagnosed and planning to undergo or recently completed a radiation or surgical oncology consult at University of California, San Francisco (UCSF)
  • •Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
  • •English-speaking and able to participate in study teleconferences
  • •Ability to understand and willingness to sign a written informed consent document
  • •Access to a device and internet connection sufficient for teleconference participation

排除标准

  • •Prior definitive treatment for prostate cancer (e.g., surgery, radiation, or systemic therapy)
  • •Cognitive, sensory, or language impairment that would interfere with the ability to understand, participate in, or complete the study procedures
  • •Inability or unwillingness to participate in two study-related teleconferences
  • •Current enrollment in another interventional clinical trial that may interfere with study participation
  • •Inability to comply with protocol requirements (e.g., completing surveys or using the information-tracking log)

研究组 & 干预措施

Intervention Arm

Experimental

AI teleconferences with Large Language Model (LLM) interaction

干预措施: Questionnaires (Behavioral)

Control Arm

Placebo Comparator

AI teleconferences without LLM interaction

干预措施: Questionnaires (Behavioral)

Intervention Arm

Experimental

AI teleconferences with Large Language Model (LLM) interaction

干预措施: AI-guided COUNSEL Intervention (Behavioral)

结局指标

主要结局

Mean differences on EORTC QLQ-INFO25 - Patient-Perceived Cancer-Related Information

时间窗: Up to 2 days

Patient-perceived quality, breadth, and depth of cancer-related information received following an oncology consultation, as measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-INFO25) survey. The EORTC QLQ-INFO25 comprises four multi-item scales and eight single items to assess the level and quality of information received by cancer patients. Scores for all scales and single items range from 0-100. The survey uses a 4-point Likert scale (1 = "not at all' to 4 = "very much") and some yes/no questions. Higher scores represent a greater patient-perceived level of shared decision-making. Mean differences between treatment groups will be reported with 95% confidence intervals, along with Hedges' g effect sizes. A Mann-Whitney U test will be used for sensitivity analysis.

次要结局

  • Mean differences on SDM-Q-9 and SDM-Q-Doc - Patient- and Provider-Perceived Shared Decision Making(Day 21)
  • Mean differences on NCCN Distress Thermometer - Patient-Reported Distress(Up to 21 days)
  • Patient-Provider Concordance in Shared Decision Making(Day 21)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验